API Trade Surplus: A Closer Look

The reported trade surplus in active pharmaceutical ingredients (APIs) looks positive for India's drug sector. However, a closer look reveals structural dependencies that government efforts are trying to fix, especially reliance on China for vital raw materials.

Trade Balance Masks Rising China Share

Minister J.P. Nadda highlighted India's API exports exceeding imports by about ₹2,280 crore in the last fiscal year. This surplus, while good on paper, doesn't show the rising cost of imported APIs, which hit ₹39,215 crore in FY2025. A significant part of this import bill, ₹29,064 crore, came from China, increasing China's share of India's API imports to 74% from 70% in FY2023. This growing import reliance for basic components, despite the overall export surplus, highlights a consistent vulnerability in India's domestic drug supply chain.

Global API Market and India's Standing

The global Active Pharmaceutical Ingredients (API) market is substantial, valued at about $245 billion in 2025 and expected to reach between $348 billion and $445 billion by 2031-2035, growing at a compound annual rate of roughly 7.25%. India is a major player, ranking third globally in API production volume with an 8% share of the world market. However, recent trends show China surpassing India in new API Drug Master File (DMF) filings in 2024, showing its rapidly growing manufacturing scale. While India holds a leading share (48%) of total active API DMFs for U.S. medicines, China's increasing filings signal a shift in global manufacturing power. Competitor nations like Vietnam are also emerging, using cost-effectiveness and government support to boost their API manufacturing capabilities.

PLI Scheme Aims for Self-Sufficiency

The Indian government's Production Linked Incentive (PLI) scheme, backed by a ₹6,940 crore outlay, aims to counter import dependence and boost domestic manufacturing of APIs, Key Starting Materials (KSMs), and drug intermediates. The scheme has helped establish approximately 56,800 tonnes per annum of domestic manufacturing capacity for 28 critical products. By December 2025, it reported cumulative sales of ₹2,720 crore, with ₹527.96 crore in exports, effectively avoiding imports worth ₹2,192.04 crore. While these figures show progress in building capacity and reducing imports, the scheme faces the challenge of building a complete value chain, not just downstream production. The scheme encourages backward integration, pushing for more local chemical sourcing and investments in in-house KSM units to secure supply chains.

Broader Pharma Sector Performance

The wider Indian pharmaceutical industry, a key economic contributor, is projected to reach $130 billion by 2030, with a turnover of ₹4.17 lakh crore in FY2023-24. The sector's overall P/E ratio is around 32.9x, slightly below its three-year average, suggesting investors might be more cautious or valuations are shifting. Major companies like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Aurobindo Pharma lead the market, with varying P/E ratios reflecting different growth prospects. For example, Sun Pharma trades at a P/E of 39.50x, Dr. Reddy's at 19.20x, and Aurobindo Pharma at 20.50x, indicating different investor perceptions of their value. Despite strong industry growth, India's overall trade deficit remained significant, reaching $34.68 billion in January 2026, highlighting broader economic import pressures.

Risks and Vulnerabilities

Despite government efforts, the reliance on China for APIs and KSMs remains a major vulnerability. Concentrating API manufacturing in limited regions, including China, heightens the risk of supply chain disruptions, as seen in past global events. If prices for Chinese KSMs become volatile, it can squeeze profit margins for Indian manufacturers, especially small and medium ones, potentially halting production or delaying upgrades. Furthermore, while India has seen fewer serious regulatory findings by the USFDA in 2025, some facilities, like Sun Pharmaceutical Industries' Halol plant, still face 'Official Action Indicated' (OAI) classifications, showing ongoing compliance issues that can lead to import bans. While boosting capacity, the scheme risks over-reliance on incentives if domestic R&D in advanced chemistries, like fermentation and high-potency APIs, doesn't keep pace. The competitive landscape is also changing, with countries like Vietnam investing in API production, potentially challenging India's cost advantages long-term.

Outlook for India's Pharma Sector

India's pharmaceutical sector is expected to reach $130 billion by 2030, driven by rising domestic demand, export growth, and government support. Analysts expect continued growth, though rates will vary by segment and market definition. The government aims for long-term self-sufficiency in the pharma sector to reduce strategic risks and boost global competitiveness. Future success will hinge on the private sector's timely capital investments, developing expertise in advanced chemistries, and achieving backward integration beyond PLI-backed manufacturing.